Peanut Allergy Treatment Market Analysis

Peanut Allergy Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on route of administration, the market is segmented into injectable, oral, and other routes of administration. The injectable segment held the majority of market share in 2023 of about 51.4%.
 

• Injections find extensive use in delivering epinephrine and immunotherapeutic treatments such as Dupixent (Regeneron Pharmaceuticals and Sanofi). Immunotherapeutic treatments target specific pathways in the immune system and require their delivery directly into the bloodstream, ensuring rapid and specific action. As a result, the adoption of injection as a preferred route of administration has increased globally.
   
• Injections are often administered at intervals (weekly/monthly), which makes them more convenient for patients and increases patient compliance compared to oral therapies. Furthermore, injectable biologics are used for treating multiple autoimmune allergic conditions that makes injections a preferred option for patients with multiple allergies.
   

Based on drug class, the peanut allergy treatment market is classified into epinephrine, antihistamines, immunotherapies, and other drug classes. The epinephrine segment dominated the market with a revenue of about USD 233 million in 2023.
 

• Growing use of epinephrine injections as an emergency injection (first-line treatment) for treating severe peanut allergies is driving the revenue growth of the segment. Epinephrine helps to reverse any life-threatening symptoms such as swelling of the airway and low blood pressure and thus is commonly prescribed for use during life threatening situations.
   
• Additionally, epinephrine injections are among the commonly prescribed injections for other food allergies, which has eased their availability across pharmacies, increasing their adoption among allergic patients globally. Furthermore, many patients with peanut allergies carry epinephrine autoinjectors, that are easy to use and can be self-administered.
   

Based on distribution channels, the peanut allergy treatment market is classified into hospital pharmacies, retail pharmacies, and other distribution channels. The hospital pharmacies segment dominated the market with a revenue of about USD 267.8 million in 2023.
 

• The dominating share of the hospital pharmacies can be attributed to an easy availability of specialized treatments such as oral immunotherapeutic drugs across them due to their specialized nature and the need for close monitoring during initial doses.
   
• Moreover, hospital pharmacies often have the capability to offer compounded medications, including customized formulation of immunotherapy for peanut allergies, as a result, many patients prefer hospital pharmacies over retail pharmacies.
   

North America peanut allergy treatment market accounted for 41.3% of market share in global market in 2023 and is predicted to reach USD 531.6 million by 2032.
 

• The leading share of North America can be attributed to increasing prevalence of peanut allergies in the region. According to a September 2021 study published in the National Center for Biotechnology Information, the prevalence of peanut allergies increased by about 3.5 times since 1997, reaching 1.5-2% in the U.S. Owing to an increasing prevalence of peanut allergies, the demand for its treatment has surged in the region.
   
• Moreover, increasing approval of immunotherapies is also contributing to the revenue growth in the market in North America. For instance, in February 2024, US FDA approved Xolair injection, an oral immunotherapy product for patients aged 4 to 17 years.
   

The U.S. peanut allergy treatment market was valued at USD 174.1 million in 2023 and is anticipated to grow at a CAGR of 11.7% over the forecast period.
 

• Increasing awareness for peanut allergies in the U.S. through awareness campaigns has surged the number of parents opting for early peanut exposure to their infants for timely diagnosing peanut allergies. According to the National Peanut Board, since 2001, Farmers in the U.S. have invested more than USD 36 million to help solve the peanut allergy issues through educational and research outreach.
   
• Furthermore, increasing investments in the country for developing new therapeutic candidates to effectively treating allergies is also contributing to an increasing availability of approved treatments options in the country. For instance, in July 2021, Vedanta Biosciences, Inc. received USD 68 million series D financing for various pipeline candidates including VE416 for treating peanut allergy. Such investments are driving the research and developments activities in the country.
   

Germany peanut allergy treatment market is expected to show lucrative growth opportunities during the forecast period.
 

• Growing awareness for peanut allergies in the Germany due to high incidence of fatal food allergies is driving the demand for its timely treatment. According to an October 2023 article from American Association of Allergy, Asthma & Immunology, Germany reported a total of about 305 fatal allergic reactions among children and adults due to drugs, insects, and food. As a result, the parents in Germany are increasingly opting for timely diagnosis of allergies, thereby increasing the demand for its timely treatment.
   
• Furthermore, presence of advanced pharmaceutical research and development and manufacturing facilities in Germany is attracting vendors to increasingly collaborate with the local contract manufacturing organizations and contract research organizations to boost their pipeline production for use in clinical studies. For instance, Allergy therapeutics plc announced its collaboration with Germany based AGC Biologics for scaling up Polyvac peanut product to be used in clinical studies.
   

Australia peanut allergy treatment market is anticipated to show remarkable growth over the coming years.
 

• High incidence of peanut allergies among patients aged one year is driving the demand for treating peanut allergies. According to the Allergy and Anaphylaxis Australia, about 3% of children of age one year suffer from peanut allergies. However, owing to significant awareness among parents, about 20% of children grow out of their peanut allergies. Increased awareness in the Australia together with high incidence of peanut allergy is contributing to its increasing growth in the market.
   
• Additionally, growing support from government in pharmaceutical research for developing novel therapeutic candidate for peanut allergies is also contributing to the growth of market in Australia. In January 2023, Government of Australia invested about USD 12 million in Avarax, a company involved in developing breakthrough immunotherapeutic treatment for peanut allergy. Growth in funding for peanut allergy therapies from government and private organizations in Australia is expected to offer lucrative growth opportunities to the vendors during the forecast period.